logo
These Are The Vehicles Data Shows Are The ‘Most American' For 2025

These Are The Vehicles Data Shows Are The ‘Most American' For 2025

Forbes17-06-2025
The Tesla Model 3 was named the "most American" car for 2005 based on a study conducted by Cars.com.
In decades past, the concept of 'Buy American' with regard to car, truck and SUV purchases was largely patriotic, supporting domestic automakers and their union autoworkers against the onslaught of what had been a tsunami of increasingly popular import models reaching U.S. shores in the 1980's.
It's now becoming a crucial financial consideration, thanks to import tariffs being slapped on vehicles and components imported from other countries. In addition to vehicles imported directly to the U.S., this includes domestic-branded cars and trucks assembled in Canada and Mexico, and the multitude of parts sourced from China, not to mention a hefty tariff being slapped on imported steel.
Some brands say they are in the position to absorb the added costs, at least for the time-being, while others will have no choice but to pass along all or part of the tariffs on to consumers and/or readjust their model mixes accordingly. Sources predict hikes to wind up as high as $5,000 to $10,000 on imported vehicles and $2,000-$3,000 on those built within U.S. borders.
What will surely muddy the proverbial waters for consumers is the fact that the lines between what is a domestic and what is an import vehicle have narrowed considerably over the years.
More Asian and European brands (Hyundai, Kia, BMW, etc.) have been setting up shop to both build and sell vehicles to U.S. car buyers and even export them to other countries. The traditional 'Big Three' domestic brands now build or all or part of certain vehicle lines in Canada (Chevrolet Silverado 1500) and Mexico (Ford Maverick, GMC Sierra 1500), with some crossing borders more than once on the way to dealers' showrooms. Some are imported entirely from other countries like South Korea (Buick Encore GX and Envista), and are rebranded for U.S. sales
To help consumers make informed choices in this regard, and being especially valuable to help them skirt as much as any added-on tariff costs as possible, Cars.com has compiled its annual American-Made Index that details which cars, trucks and SUVs can be considered the 'most-American' vehicles for the 2025 model year.
The study found that Tesla vehicles are by far the purest domestic rides on the road, with the Models 3, Y, S and X topping the list in that order. Eight models among the top 20 come from Honda/Acura, which in and of itself shatters the notion of what is and what isn't a true American vehicle.
Two of the only three domestic-badged entries among the top 20 come from Jeep, a brand with bona fide patriotic roots, with the other being the Chevrolet Colorado pickup truck. Counting the Teslas, seven of the 20 most American models are either full electric or hybrid-powered models.
However, what most might consider the most American vehicle of all, the industry's top-selling Ford F-150 full-size pickup truck, winds up at number 37 on the website's domestic-content list. That's 30 places below the seventh-ranked midsize car-based Honda Ridgeline pickup by virtue of the latter being built exclusively in the U.S. using higher percentages of domestic content.
The lowest-ranked domestic-badged model is the full-electric Cadillac Lyriq, sitting at number 98 out of 99 vehicles ranked, with the list being anchored by the Toyota RAV4 Hybrid. only sitting above the Toyota RAV4 Hybrid in this regard. Of note, all of the 99 models on the Most American list have at some component of final assembly in the U.S.
You can find Cars.com's Most-American Index with all 99 models ranked here.
Ratings are based on five key factors graded on a 100-point basis: the location of final assembly; the U.S. manufacturing workforce employed (if any); the percentage of U.S. and Canadian-sourced parts; the country of origin for available engines and the countries of origin for available transmissions.
Much of this information is required by federal law to be included on the pricing sticker affixed to all light-duty vehicles sold in the U.S.. Consumers can also long onto the National Highway Traffic Safety Administration (NHTSA) website, which posts the percentages of domestic and foreign content in cars from past and current model years.
One significant caveat, however, is that the above-mentioned labeling law treats Canadian (though not Mexican) parts and assembly as essentially coming from the U.S. The Cars.com American Made Index helps to compensate for this anomaly by factoring in the countries of origin for engines and transmissions, as noted above, to more prominently weigh in a given model's two most cost-intensive components.
Also, since federal requirements don't mandate calling it out, Cars.com analyzes each automaker's domestic workforce that's directly involved in vehicle assembly and parts manufacturing, and factors that data against that manufacturer's U.S. output relative to the industry overall.
Excluded are heavy-duty vehicles, low-production models and those not yet on the market as of spring 2023 or ones that are being discontinued or with production being moved overseas.
Source: Cars.com's American Made Index 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...

Yahoo

time19 minutes ago

  • Yahoo

Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...

Net Loss: $33.5 million or $0.58 per share for Q1 2025, compared to $31.4 million or $0.54 per share in Q4 2024. Cash and Investments: $52.5 million as of March 31, 2025. Debt Reduction: Total debt reduced by $10 million, with near-term repayment obligations lowered from $118 million to $17 million. OMIDRIA Royalties: $6.7 million for Q1 2025 based on net sales of $22.3 million, down from $10.1 million in Q4 2024. Interest Expense: $3.7 million for Q1 2025, reflecting a $477,000 increase from Q4 2024. Operating Expenses: $35 million for Q1 2025, a decrease of $691,000 from Q4 2024. Income from Discontinued Operations: $4.1 million for Q1 2025, down $1.1 million from Q4 2024. Warning! GuruFocus has detected 2 Warning Signs with OMER. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Omeros Corp (NASDAQ:OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million. The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital. The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25. Omeros Corp (NASDAQ:OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access. The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse. Negative Points Omeros Corp (NASDAQ:OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter. The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA. There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline. OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue. Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes. Q & A Highlights Q: Can you provide details on the launch plans for narsoplimab and its impact on patient access? A: Greg Demopulos, Chairman & CEO, stated that the company is well-prepared for the launch, expecting it to be successful. Nadia Dac, Chief Commercial Officer, elaborated that the team is focused on the top 40 transplant centers responsible for 60% of the allogeneic transplant volume. They have identified key decision-makers and are engaging with payers, emphasizing narsoplimab's unique value as the only approved treatment for TA-TMA. Q: Can you provide more information about the patients affected by TA-TMA and the associated healthcare costs? A: Greg Demopulos explained that TA-TMA is an unpredictable complication of stem cell transplants, often resulting in rapid deterioration and high mortality. Nadia Dac added that untreated patients incur significant costs, such as ICU stays and organ failure treatments. Narsoplimab aims to reduce these costs by offering an effective outpatient treatment option. Q: How are you managing the financial aspects of the company, particularly regarding debt and capital raising? A: Greg Demopulos highlighted the recent exchange agreement that reduced the 2026 convertible notes' principal, lowering near-term repayment obligations by over $100 million. The company is also exploring partnerships for non-dilutive funding and has an active at-the-market facility to raise up to $150 million. Q: What are the strategic priorities for Omeros beyond narsoplimab? A: Greg Demopulos mentioned that the company is prioritizing the development of zaltenibart for paroxysmal nocturnal hemoglobinuria (PNH) and continuing its PDE7 inhibitor program for cocaine use disorder, funded by a NIDA grant. They are also advancing their oncology platform, Oncotox, targeting acute myeloid leukemia. Q: What is the current status of the narsoplimab BLA resubmission and its potential market impact? A: Greg Demopulos confirmed that the FDA has accepted the resubmitted BLA for narsoplimab in TA-TMA, with a target action date of September 25. The company anticipates narsoplimab to be the first approved therapy for TA-TMA, addressing a nearly $1 billion annual market opportunity. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...
Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...

Yahoo

time19 minutes ago

  • Yahoo

Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...

Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a significant milestone by reporting positive EBITDA for the first time in its history, indicating a path towards profitability. The company reported a 21% increase in revenue for the first quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of its technology. Biotricity Inc (BTCY) has expanded its cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's Tensorflow, enhancing diagnostic accuracy and patient outcomes. The company has secured regulatory approvals in multiple international markets, including Canada, Saudi Arabia, and Argentina, aligning with its strategy for global expansion. Gross profit for the quarter increased by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%, reflecting operational efficiencies and a strong recurring revenue base. Negative Points Despite improvements, Biotricity Inc (BTCY) reported a net loss of $754,000 for the first quarter, although this was a significant improvement from the prior year's loss. The company faces challenges with rising variable interest rates, which could impact future financial performance. Biotricity Inc (BTCY) is still in the process of pursuing FDA clearance for its AI clinical model, which could delay the full commercialization of its new technologies. Operating expenses, although reduced, remain a concern as the company continues to invest in R&D and sales force transformation. The company's expansion into new verticals and international markets may require significant resources and could face regulatory and competitive challenges. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with BTCY. Q: Can you provide more details on the strategic partnerships mentioned in the call? A: Dr. Walkus Al Sadiq, CEO, highlighted that Biotricity has formed strategic partnerships with industry giants like Amazon AWS and Google's Tensorflow to expand their cardiac AI cloud platform. These partnerships are crucial for enhancing diagnostic accuracy and improving patient outcomes. Additionally, alliances with three major group purchasing organizations (GPOs) in the US provide access to approximately 90% of hospitals, significantly expanding market access. Q: What are the financial highlights for the first quarter of fiscal 2026? A: Johnny Abo, CFO, reported a 21% increase in revenue to $3.9 million compared to the previous year. Gross profit rose by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%. Operating expenses decreased by 18.5%, and the company achieved a positive EBITDA of $333,000, marking the first quarter of positive EBITDA in Biotricity's history. Q: How is Biotricity addressing the market for atrial fibrillation monitoring? A: The CFO emphasized that atrial fibrillation, a major contributor to strokes, remains a significant focus. Biotricity's technology has monitored over 2 trillion heartbeats, providing early intervention opportunities and improving patient outcomes. This focus not only enhances patient care but also offers potential healthcare cost savings. Q: What are the future growth prospects for Biotricity? A: Dr. Walkus Al Sadiq, CEO, expressed optimism about future growth through the commercialization of products like Biocore Pro, Bioflux, and Biocare. The company is committed to advancing remote monitoring solutions and expanding its geographic footprint, with regulatory approvals in Canada, Saudi Arabia, Argentina, and other markets. Q: How has Biotricity managed to achieve cost efficiencies? A: The CFO explained that cost efficiencies were achieved through strategic transformation of the sales force, focusing on larger accounts and longer sales cycles. Additionally, the use of AI and automation, along with proactive cost management, contributed to positive free cash flows and a path towards profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...
Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...

Yahoo

time19 minutes ago

  • Yahoo

Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...

Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Beeline Holdings Inc (NASDAQ:BLNE) successfully divested its spirits assets, allowing a full focus on its core digital mortgage lending business. The company reported a 27% increase in revenue and a 40% decrease in expenses in Q2 2025 compared to Q1 2025. Beeline Holdings Inc (NASDAQ:BLNE) introduced a new equity product that is not tied to interest rates, providing a competitive advantage. The AI sales agent, Bob, significantly improved lead conversion and mortgage application rates, contributing approximately $150,000 in revenue. The company reduced its debt by $6.2 million in 2025, aiming to be debt-free by November 1, 2025, and cash flow positive by January 2026. Negative Points The market remains challenging due to higher interest rates affecting refinance and purchase transactions. The company reported a net loss from continuing operations of $4 million for Q2 2025. There were $500,000 in one-time non-recurring expenses in Q2, impacting financial results. The broader launch of the new equity product has been delayed to ensure proper execution and customer satisfaction. Despite improvements, the company still faces significant scaling challenges and uncertainties in its new product offerings. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with BLNE. Q: Can you provide more details about the home equity cash-out product and the timing of its broader launch? A: (Nick Lauza, CEO) We initially planned to launch in late August or early September but decided to delay to ensure we get it right. The opportunity is massive, with untapped equity in the US market. The Genius Act provides regulatory clarity, and we want to ensure the product is perfect before scaling. We will conduct a select number of transactions over the next 30 to 45 days to gather feedback and ensure consumer interests are prioritized. Q: What are the assumptions behind your profitability projections for late this year or early next year? A: (Nick Lauza, CEO) We are focusing on achieving profitability quickly by cutting $225,000 in monthly recurring expenses, which will be fully realized by September. Our locks are up, and we've reduced our marketing budget by $40,000 monthly while maintaining strong performance. We also had $500,000 in one-time expenses in Q2, which won't recur. We aim to be debt-free by November 1 and cash flow positive by January 2026. Q: Can you explain the economics of the fractional products and the expected volume at scale? A: (Nick Lauza, CEO) Our margins will be higher than our mortgage products, with less work involved since we're underwriting the property, not the consumer. We expect about 33% more revenue per file. Marketing expenses will be minimal as our partner will drive the business. We've identified about 1,000 potential customers who would qualify for this product. Q: What will drive significant growth in 2026, even without rate cuts? A: (Nick Lauza, CEO) We expect strong demand for Beeline Equity, as it provides liquidity based on home equity rather than individual qualifications. This product is ideal for those who can't qualify for cash-out refis or HELOCs. Additionally, our mortgage business is improving, and we have a strong title business team. We anticipate the equity product to be our largest revenue generator in 2026, followed by the mortgage and title businesses. Q: Do you have a sensitivity analysis for how rate cuts could impact growth? A: (Nick Lauza, CEO) While we don't have specific figures, a 25 basis point cut would significantly impact our business as a centralized digital lender. Digital models perform better in low-rate environments, and a 1-point cut would lead to rapid growth. (Chris Moe, CFO) Additionally, the longer rates remain high, the more significant the impact of a cut due to pent-up demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store